Semaglutide reduces risk for MACE in patients with obesity and heart failure
By
Haymarket Media
Aug 28, 2024
MACE, heart failure composite end point, cardiovascular death and all-cause death all improved with semaglutide for patients with versus without heart failure.
Mean cost of bringing new drug to US market Is $879.3 million
Jul 02, 2024
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
New COVID-19 drug guards against all variants in immunocompromised
Apr 28, 2023
The trial results could be out by September and may lead to the FDA emergency use authorization.
Major drug shortages not likely after tornado damages Pfizer plant, FDA says
Jul 24, 2023
Pfizer is working to repair the damage and mitigate any shortage of drugs made at the facility.
ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
ACC: Empagliflozin cuts heart failure hospitalization risk after AMI
Apr 08, 2024
Lower risks for first heart failure hospitalization and total heart failure hospitalization were seen with empagliflozin.
Cyberattack stalls prescription dispensing at UnitedHealth
Feb 27, 2024
This latest cyberattack underscores the vulnerability of healthcare data, particularly the privacy of patients’ personal information.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...